Deschloroketamine hydrochloride CRM, also known as DCK, is a dissociative anesthetic drug that has gained popularity in recent years for its recreational use. It is a research chemical that was first discovered in 1950 by Parke-Davis, and later studied by chemist David E. Nichols in the 1980s. It belongs to the arylcyclohexylamine class of compounds, which also includes ketamine and phencyclidine (PCP). DCK is often used by individuals seeking to achieve a disassociative state of mind, similar to that produced by ketamine, while avoiding the negative side effects associated with the latter.
Chemical name:
Deschloroketamine hydrochloride CRM is chemically known as 2-Phenyl-2-(methylamino)cyclohexanone hydrochloride. Its molecular formula is C13H17NO•HCl, and its molecular weight is 259.75 g/mol.
CAS No:
Deschloroketamine hydrochloride CRM has a CAS No of 4631-27-0.
Top ten keywords from Google and Synonyms:
Health benefits of this product:
Deschloroketamine hydrochloride CRM is not approved for medical use and there are no health benefits associated with its consumption.
Potential effects:
The effects of Deschloroketamine hydrochloride CRM can vary depending on the dosage, method of consumption, and individual tolerance. In general, the drug produces a dissociative state of mind that is similar to that produced by ketamine. Users may experience euphoria, altered perception of time and space, visual and auditory hallucinations, and a sense of detachment from their surroundings. The drug can also cause sedation, confusion, and impaired motor coordination. At higher doses, Deschloroketamine hydrochloride CRM can cause blackouts, memory loss, and delirium.
Product mechanism:
Deschloroketamine hydrochloride CRM works by inhibiting the activity of the N-methyl-D-aspartate (NMDA) receptor in the brain. This receptor is involved in regulating the transmission of signals between neurons, and plays a key role in learning, memory, and perception. By blocking the NMDA receptor, Deschloroketamine hydrochloride CRM disrupts the normal functioning of these processes, leading to the characteristic dissociative effects of the drug.
Safety:
Deschloroketamine hydrochloride CRM is a relatively new drug, and little is known about its long-term safety profile. However, like other arylcyclohexylamine drugs, it is thought to have a low risk of overdose and toxicity compared to other classes of drugs. Nevertheless, users should exercise caution when consuming Deschloroketamine hydrochloride CRM and be mindful of the potential risks and side effects associated with its use.
Side effects:
Some common side effects of Deschloroketamine hydrochloride CRM include dizziness, nausea, vomiting, and headache. The drug can also cause dry mouth, blurred vision, and difficulty urinating. At higher doses, users may experience more severe side effects such as confusion, agitation, and paranoia. Long-term use of Deschloroketamine hydrochloride CRM can lead to cognitive impairment and memory loss.
Dosing information:
Since Deschloroketamine hydrochloride CRM is not approved for medical use, there are no established dosing guidelines. Users should start with a small dose and gradually increase as needed, taking care to avoid taking too much at once. It is important to note that the potency of Deschloroketamine hydrochloride CRM can vary widely depending on the source and purity of the drug, so users should exercise caution and always test their substances before consuming them.
Conclusion:
Deschloroketamine hydrochloride CRM is a dissociative anesthetic drug that is gaining popularity among individuals seeking to achieve a disassociative state of mind. While it shares some similarities with ketamine, it is thought to have a lower risk of toxicity and overdose. Nevertheless, users should be aware of the potential risks and side effects associated with its use. As a research chemical, it is not approved for medical use and there are no established dosing guidelines. Those considering using Deschloroketamine hydrochloride CRM should take great care to ensure their safety and well-being
